IGI Logo

Glenmark Pharmaceuticals is currently trading at Rs. 896.20, up by 8.05 points or 0.91 % from its previous closing of Rs. 888.15 on the BSE.

The scrip opened at Rs. 898.85 and has touched a high and low of Rs. 898.85 and Rs. 892.05 respectively. So far 3031 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 901.45 on 02-Jan-2024 and a 52 week low of Rs. 369.50 on 30-Jan-2023.

Last one week high and low of the scrip stood at Rs. 901.45 and Rs. 829.00 respectively. The current market cap of the company is Rs. 25060.76 crore.

The promoters holding in the company stood at 46.65 % while Institutions and Non-Institutions held 35.15 % and 18.21 % respectively.

Glenmark Pharmaceuticals has launched a biosimilar of the popular anti?diabetic drug, Liraglutide, for the first time in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI). Priced at around Rs 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by around 70%, and will be available only under prescription.

Liraglutide belongs to the class of glucagon?like peptide 1 receptor agonist (GLP?1 RA) drugs, which increase glucose?dependent insulin secretion and decrease in appropriate glucagon secretion. It has been approved globally for the management of type 2 diabetes mellitus in adult patients in the United States and the European Union.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.